A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT06010303 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

Interventions

DRUG: LBL-007
DRUG: Tislelizumab
DRUG: Chemotherapy Doublet

Sponsor

BeiGene